Primary outcome: partial clinical response · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in number with partial response at one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Number with treatment failure by one year · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to lower number with treatment failure by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Frequent relapses · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus may leads to lower number with frequent relapses by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Number with steroid resistance by one year · idiopathic steroid‐resistant nephrotic syndrome in children
Tacrolimus showed no clear difference in number with steroid resistance by one year compared with mycophenolate mofetil to maintain remission (low certainty).
1 finding from 1 review
Change in GFR · idiopathic steroid‐resistant nephrotic syndrome in children
1 finding from 1 review
Non‐initiation of breastfeeding · women with a pre‐pregnancy BMI > 29 kg/m², who were intending to breastfeed, had no history of breast surgery, who were at least 19 years…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Exclusive breastfeeding at 4‐6 weeks · women with a pre‐pregnancy BMI > 29 kg/m², who were intending to breastfeed, had no history of breast surgery, who were at least 19 years…
It is very uncertain whether physical breastfeeding support interventions (electric or manual… changes exclusive breastfeeding at 4‐6 weeks compared with usual care (no pump) (very low certainty).
1 finding from 1 review
Breastfeeding · women with a pre‐pregnancy BMI > 29 kg/m², who were intending to breastfeed, had no history of breast surgery, who were at least 19 years…
It is very uncertain whether physical breastfeeding support interventions (electric or manual… changes any breastfeeding at 4‐6 weeks compared with usual care (no pump) (very low certainty).
2 findings from 1 review
Exclusive breastfeeding at 6 months · women with a pre‐pregnancy BMI > 29 kg/m², who were intending to breastfeed, had no history of breast surgery, who were at least 19 years…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · Patients with maintenance treatment in lupus nephritis
It is very uncertain whether azathioprine (AZA) changes death compared with mycophenolate mofetil (MMF) (very low certainty).
1 finding from 1 review
ESKD · Patients with maintenance treatment in lupus nephritis
It is very uncertain whether azathioprine (AZA) changes ESKD compared with mycophenolate mofetil (MMF) (very low certainty).
1 finding from 1 review
Renal relapse · Patients with maintenance treatment in lupus nephritis
Azathioprine (AZA) probably leads to higher renal relapse compared with mycophenolate mofetil (MMF) (moderate certainty).
1 finding from 1 review
Doubling serum creatinine · Patients with maintenance treatment in lupus nephritis
Azathioprine (AZA) may leads to higher doubling of serum creatinine compared with mycophenolate mofetil (MMF) (low certainty).
1 finding from 1 review
Major infection · Patients with maintenance treatment in lupus nephritis
Azathioprine (AZA) showed no clear difference in major infection compared with mycophenolate mofetil (MMF) (low certainty).
1 finding from 1 review
Leucopenia · Patients with maintenance treatment in lupus nephritis
Azathioprine (AZA) may leads to higher leucopenia compared with mycophenolate mofetil (MMF) (low certainty).
1 finding from 1 review
Alopecia · Patients with maintenance treatment in lupus nephritis
Azathioprine (AZA) showed no clear difference in alopecia compared with mycophenolate mofetil (MMF) (low certainty).
1 finding from 1 review
Serious maternal morbidity or death · pregnant women with gestational diabetes, between 38 ‐ 39 gestational weeks, without other maternal or fetal conditions.
It is very uncertain whether planned elective birth (induction or caesarean) changes maternal mortality or serious maternal morbidity compared with expectant management (very low certainty).
1 finding from 1 review
Caesarean section · pregnant women with gestational diabetes, between 38 ‐ 39 gestational weeks, without other maternal or fetal conditions.
It is very uncertain whether planned elective birth (induction or caesarean) changes caesarean section compared with expectant management (very low certainty).
1 finding from 1 review
Instrumental vaginal birth · pregnant women with gestational diabetes, between 38 ‐ 39 gestational weeks, without other maternal or fetal conditions.
It is very uncertain whether planned elective birth (induction or caesarean) changes instrumental vaginal birth compared with expectant management (very low certainty).
1 finding from 1 review
Perinatal mortality · pregnant women with gestational diabetes, between 38 ‐ 39 gestational weeks, without other maternal or fetal conditions.
1 finding from 1 review